Share Email Print
cover

Proceedings Paper

New stable synthetic bacteriochlorins for photodynamic therapy of melanoma
Author(s): Pawel Mroz; Ying-Ying Huang; Sahar Janjua; Timur Zhiyentayev; Christian Ruzié; K. Eszter Borbas; Dazhong Fan; Michael Krayer; Thiagarajan Balasubramanian; Eun Kyung Yang; Hooi Ling Kee; Dewey Holten; Jonathan S. Lindsey; Michael R. Hamblin
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and has afforded highly encouraging results in skin cancers such as basal cell carcinoma. However, pigmented melanoma remains a notable exception from the range of tumors treated by PDT largely due to the fact that melanin has high absorption of light in wavelength regions where most clinically approved photosensitizers (PS) absorb light (600-690 nm). Moreover, melanoma cells sequester exogenous molecules including photosensitizers inside melanosomes. The aforementioned drawbacks of the clinically used PS have motivated us to search for new classes of PS with improved spectral properties, such as bacteriochlorins (BC) to be used in PDT of melanoma. To overcome the PDT-resistance mechanisms of melanoma, particularly the high optical absorption of melanin, three near-infrared (NIR) absorbing synthetic stable BC were used in PDT treatment of melanoma. Dose and fluence dependent cell killing, intracellular localization (particularly in melanosomes), and correlation between the melanin level and cell death were examined. Intracellular melanosomes are ruptured after illumination as shown by electron microscopy. The best in vitro performing BC were tested upon delivery in micellar nanoparticles against a mouse pigmented melanoma. Two of the BC were effective at significantly lower concentrations (<0.5 μM) than common photosensitizers in present use.

Paper Details

Date Published: 13 July 2009
PDF: 14 pages
Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73802S (13 July 2009); doi: 10.1117/12.823060
Show Author Affiliations
Pawel Mroz, Wellman Ctr. for Photomedicine, MGH (United States)
Harvard Medical School (United States)
Ying-Ying Huang, Wellman Ctr. for Photomedicine, MGH (United States)
Harvard Medical School (United States)
Sahar Janjua, Wellman Ctr. for Photomedicine, MGH (United States)
Aga Khan Medical College (Pakistan)
Timur Zhiyentayev, Wellman Ctr. for Photomedicine, MGH (United States)
M.V. Lomonosov Moscow State Univ. (Russian Federation)
Christian Ruzié, North Carolina State Univ. (United States)
K. Eszter Borbas, North Carolina State Univ. (United States)
Dazhong Fan, North Carolina State Univ. (United States)
Michael Krayer, North Carolina State Univ. (United States)
Thiagarajan Balasubramanian, NIRvana Pharmaceuticals, Inc. (United States)
Eun Kyung Yang, Washington Univ. in St. Louis (United States)
Hooi Ling Kee, Washington Univ. in St. Louis (United States)
Dewey Holten, Washington Univ. in St. Louis (United States)
Jonathan S. Lindsey, North Carolina State Univ. (United States)
Michael R. Hamblin, Wellman Ctr. for Photomedicine, MGH (United States)
Harvard Medical School (United States)
Harvard-MIT Division of Health Sciences and Technology (United States)


Published in SPIE Proceedings Vol. 7380:
Photodynamic Therapy: Back to the Future
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top